Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ethicon, Inc.
With
OMRIX Biopharmaceuticals
The time it will take to stop bleeding will be measured and compared between patients who are treated with fibrin sealant 2 to those who are treated with Surgicel®.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female subjects requiring non-emergent retroperitoneal or intra-abdominal surgical procedures
Presence of an appropriate soft-tissue target bleeding site (challenging bleeding site for which topical hemostatic adjuncts might typically be used) as identified intra-operatively by the surgeon
Subjects must be willing to participate in the study and provide written informed consent
You may not be if
Subjects undergoing emergency surgery
Parenchymal or anastomotic bleeding sites will not be considered for randomization
Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
Subjects with known intolerance to blood products or to one for the components of the study product
Subjects unwilling to receive blood products
Subjects with known autoimmune immunodeficiency diseases (including known HIV
Subjects who are known, current alcohol and/or drug abusers
Subjects who have participated in another investigational drug or device research study within 30 days of enrollment